Indicatie
Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ? 21 years old at initial diagnosis.
In andere landen
Dezelfde werkzame stoffen in andere registers, met hetzelfde merk eerst.
Nationale vermeldingen
De nationale registers waarin dit EU-geneesmiddel staat.
- Evoltra 1 MG/ML Concentrado Para Solucion Para PerfusionSpanje · 0,01 mg · concentrado para solución para perfusión · Sanofi B.V.Zelfde merk
- Evoltra 1 MG/ML Concentrado Para Solucion Para PerfusionSpanje · 1 mg · concentrado para solución para perfusión · Sanofi B.V.Zelfde merk
- EvoltraKroatiëZelfde merk